Design of Two Randomized, Placebo-Controlled, Phase 3 Trials of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Systemic Lupus Erythematosus

作者：Cristina Arriens, Eric F. Morand, Anca Askanase, Richard Furie, Ronald van Vollenhoven, Yoshiya Tanaka, Kevin Connors, Monica Davey, Kimberly A. Young, Giovanni Franchin, Richard Meier, Vaishali Shah, Carolina Leite de Oliveria, Coburn Hobar · 发表于：Advances in Therapy · 年份：2025 · DOI：10.1007/s12325-025-03299-0 · 被引用次数：3 · 研究领域：Systemic Lupus Erythematosus Research、Cytokine Signaling Pathways and Interactions、Melanoma and MAPK Pathways